Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2017 17:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
January 06, 2017 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
December 29, 2016 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the Biotech Showcase™

TORONTO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
December 21, 2016 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology

TORONTO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
November 29, 2016 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the LD Micro Main Event

TORONTO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
November 25, 2016 07:45 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
October 14, 2016 09:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference

TORONTO, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
October 13, 2016 23:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Third Quarter 2016 Results

TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
October 11, 2016 16:46 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt

TORONTO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
October 07, 2016 18:35 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®

TORONTO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...